Evidence map›Paper›PMID 23269912›Full record

ArticleFrontiers in neuroscience2012

Systems biology, bioinformatics, and biomarkers in neuropsychiatry.

Ali Alawieh, Fadi A Zaraket, Jian-Liang Li, Stefania Mondello, Amaly Nokkari, Mahdi Razafsha, Bilal Fadlallah, Rose-Mary Boustany, Firas H Kobeissy

Abstract read
In one paragraph

Article in Frontiers in neuroscience, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Exploring Biomarkers for Alzheimer's Disease.Journal of clinical and diagnostic research : JCDR · 2016
    Review
  11. Biomarkers in Psychiatry - A Critique.Annals of neurosciences · 2016
    Article
  12. Review
  13. Article
  14. Review
  15. Molecular network analysis enhances understanding of the biology of mental disorders.BioEssays : news and reviews in molecular, cellular and developmental biology · 2014
    Review
  16. Review
  17. Biomarkers in psychiatry: how close are we?Frontiers in psychiatry · 2012
    Article
  18. Challenges and developments in research of the early stages of bipolar disorder.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ali AlawiehDepartment of Biochemistry, College of Medicine, American University of Beirut Beirut, Lebanon.
Fadi A Zaraket
Jian-Liang Li
Stefania Mondello
Amaly Nokkari
Mahdi Razafsha
Bilal Fadlallah
Rose-Mary Boustany
Firas H Kobeissy

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although neuropsychiatric (NP) disorders are among the top causes of disability worldwide with enormous financial costs, they can still be viewed as part of the most complex disorders that are of unknown etiology and incomprehensible pathophysiology. The complexity of NP disorders arises from their etiologic heterogeneity and the concurrent influence of environmental and genetic factors. In addition, the absence of rigid boundaries between the normal and diseased state, the remarkable overlap of symptoms among conditions, the high inter-individual and inter-population variations, and the absence of discriminative molecular and/or imaging biomarkers for these diseases makes difficult an accurate diagnosis. Along with the complexity of NP disorders, the practice of psychiatry suffers from a "top-down" method that relied on symptom checklists. Although checklist diagnoses cost less in terms of time and money, they are less accurate than a comprehensive assessment. Thus, reliable and objective diagnostic tools such as biomarkers are needed that can detect and discriminate among NP disorders. The real promise in understanding the pathophysiology of NP disorders lies in bringing back psychiatry to its biological basis in a systemic approach which is needed given the NP disorders' complexity to understand their normal functioning and response to perturbation. This approach is implemented in the systems biology discipline that enables the discovery of disease-specific NP biomarkers for diagnosis and therapeutics. Systems biology involves the use of sophisticated computer software "omics"-based discovery tools and advanced performance computational techniques in order to understand the behavior of biological systems and identify diagnostic and prognostic biomarkers specific for NP disorders together with new targets of therapeutics. In this review, we try to shed light on the need of systems biology, bioinformatics, and biomarkers in neuropsychiatry, and illustrate how the knowledge gained through these methodologies can be translated into clinical use providing clinicians with improved ability to diagnose, manage, and treat NP patients.

Indexed as

autismbioinformaticsbiomarkersdata miningomicsproteomicspsychiatrysystems biology

Identifiers

PMID23269912
PMCPMC3529307

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.